Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Ezetimibe

Ezetimibe: 1 brand, 16 generics; first approved Oct 25, 2002; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 16 ANDA applications approved.

Earliest patent expiry
Brands (NDA)
1
Generics (ANDA)
16
Listed patents
2
Next patent expiry
Oct 30, 2025
10 mo ago

Brand (NDA) products

Originator applications
  • ZETIARLDRS
    NDA 0214452002
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB

Generic (ANDA) products (16)

Abbreviated applications
  • EZETIMIBE
    ANDA 2111592024
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALDiscontinued
  • EZETIMIBE
    ANDA 2156932022
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • EZETIMIBE
    ANDA 2108592022
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • EZETIMIBE
    ANDA 2106732020
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • EZETIMIBE
    ANDA 2017902019
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALDiscontinued
  • EZETIMIBE
    ANDA 2115502018
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • EZETIMIBE
    ANDA 2092342017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • EZETIMIBE
    ANDA 2098382017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • EZETIMIBE
    ANDA 2088032017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • EZETIMIBE
    ANDA 2083322017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALDiscontinued
  • EZETIMIBE
    ANDA 2073112017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • EZETIMIBE
    ANDA 2039312017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • EZETIMIBE
    ANDA 0787242017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALDiscontinued
  • EZETIMIBE
    ANDA 2008312017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • EZETIMIBE
    ANDA 2043312017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • EZETIMIBE
    ANDA 0785602015
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB

Patent & exclusivity timeline

Protection horizon
202520262027TodayPatent 7612058: 2025-10-30Patent 7612058Patent 7612058*PED: 2026-04-30Patent 7612058*PED
Patent expiryExclusivity endToday

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
761205810 mo ago
U-1173
7612058*PED3 mo ago

Approval history

FDA approval span
First approval
24 yr 2 mo ago
Most recent approval
2 yr 4 mo ago

Approvals span 2002–2024 across 17 FDA applications.

Brand (NDA) 16%
Generic (ANDA) 1694%

Ezetimibe: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.